Unknown

Dataset Information

0

Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery.


ABSTRACT: Uveal melanoma (UM) is a rare malignant cancer of the eye, with up to 50% of patients dying from metastasis, for which no effective treatment is available. Due to the rarity of the disease, there is a great need to harness the limited material available from primary tumors and metastases for advanced research and preclinical drug screening. We established a platform to isolate, preserve, and transiently recover viable tissues, followed by the generation of spheroid cultures derived from primary UM. All assessed tumor-derived samples formed spheroids in culture within 24 h and stained positive for melanocyte-specific markers, indicating the retention of their melanocytic origin. These short-lived spheroids were only maintained for the duration of the experiment (7 days) or re-established from frozen tumor tissue acquired from the same patient. Intravenous injection of fluorescently labeled UM cells derived from these spheroids into zebrafish yielded a reproducible metastatic phenotype and recapitulated molecular features of the disseminating UM. This approach allowed for the experimental replications required for reliable drug screening (at least 2 individual biological experiments, with n > 20). Drug treatments with navitoclax and everolimus validated the zebrafish patient-derived model as a versatile preclinical tool for screening anti-UM drugs and as a preclinical platform to predict personalized drug responses.

SUBMITTER: Yin J 

PROVIDER: S-EPMC10141637 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery.

Yin Jie J   Zhao Gangyin G   Kalirai Helen H   Coupland Sarah E SE   Jochemsen Aart G AG   Forn-Cuní Gabriel G   Wierenga Annemijn P A APA   Jager Martine J MJ   Snaar-Jagalska B Ewa BE   Groenewoud Arwin A  

Pharmaceuticals (Basel, Switzerland) 20230415 4


Uveal melanoma (UM) is a rare malignant cancer of the eye, with up to 50% of patients dying from metastasis, for which no effective treatment is available. Due to the rarity of the disease, there is a great need to harness the limited material available from primary tumors and metastases for advanced research and preclinical drug screening. We established a platform to isolate, preserve, and transiently recover viable tissues, followed by the generation of spheroid cultures derived from primary  ...[more]

Similar Datasets

| S-EPMC10272172 | biostudies-literature
2016-05-26 | GSE73738 | GEO
| S-EPMC5481921 | biostudies-literature
| S-EPMC5540787 | biostudies-literature
| S-EPMC8698893 | biostudies-literature
| PRJNA297786 | ENA
| S-EPMC7445893 | biostudies-literature
2016-02-18 | GSE78033 | GEO
| S-EPMC5688753 | biostudies-literature
| S-EPMC8882468 | biostudies-literature